Skip directly to content

Inflammation and Immunology UK Areas of Interest

Healthcare organisations are invited to submit grant requests to our inflammation and immunology business unit for the support of independent medical and/or scientific initiatives, that are aligned to Pfizer's medical and/or scientific strategies.

 

Specifically, our inflammation and immunology unit will consider applications for research, education and service improvement in the following areas:

 

Rheumatology: Adult and paediatric populations with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondyloarthritis (AS), Axial Spondyloarthritis (axSpA) and Systemic Lupus erythematosus (SLE)

Independent Medical Grant areas to be considered for Pfizer support include:

  • Evidence generation for inflammatory arthritis and lupus, particularly the UK pathway based on Real World Data (RWD)
  • Health services research for inflammatory arthritis and lupus in the NHS setting
  • Projects exploring new models of care, such as, digital patient initiatives that improve clinician-patient communication and patient treatment experience, patient safety and/or adherence to therapy.
  • Basic science research investigating mechanisms relating to Janus Kinase (JAK) pathways and inflammation
  • Audits or observational studies of management and/or outcomes of RA and PsA patients with co-morbidities (specific populations)
  • Studies investigating treatment adherence to oral dosing and/or patient preference
  • Research exploring factors associated with failure to achieve therapeutic target
  • Stratified Medicine initiatives to better improve patient care
  • Projects optimising medical education, diagnostics, therapy and delivery of care, which may include the development of novel artificial intelligence and telemedicine approaches

 

Dermatology: Adult and paediatric populations with alopecia areata (AA), atopic dermatitis (AD), psoriasis and vitiligo

Independent Medical Grant areas to be considered for Pfizer support include:

  • Evidence generation for AA, AD, psoriasis, and vitiligo, specifically to the UK patient pathway based on RWD.
  • Health services research for AA, AD, psoriasis, and vitiligo in the NHS setting
  • Fundamental research focused on JAK pathways in skin diseases
  • Epidemiology of target skin diseases at the primary and secondary care levels in the UK. These may include Health-Related Quality of Life burden and mental health associations.
  • Economic burden of the target skin diseases to the NHS
  • Projects optimising healthcare delivery and quality improvement in AD and AA patient care
  • Research developing individualised treatment strategies in AD
  • Projects optimising medical education, diagnostics, therapy and delivery of care, which may include the development of novel artificial intelligence and telemedicine approaches

 

Gastroenterology: Adult and paediatric populations with Ulcerative Colitis (UC) and Crohn’s Disease (CD)

Independent Medical Grant areas to be considered for Pfizer support include:

  • Understanding disease management in UC and new measures of efficacy (e.g. treat to target, development of new tools, measures of efficacy, biomarkers)
  • Understanding treatment and efficacy of JAK inhibitor in severe, acute flare in UC
  • Research developing personalised medicine approaches in UK UC patients
  • Real world data generation investigating the effect of JAK inhibition in adult UC, specific to UK patient pathways
  • Projects optimising medical education, diagnostics, therapy and delivery of care in UC and CD, including the development of novel artificial intelligence and telemedicine approaches
  • Support for basic science research - investigating mechanisms relating to JAK pathways and inflammation in UC

For all independent medical grants, the grant recipient is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Pfizer must not be involved in any aspect of project development, nor its conduct or monitoring.

To discuss your potential independent medical grant application for any of the above areas, please phone 01304 616161 and ask to speak to a member of the inflammation and immunology medical affairs team.

PP-PFE-GBR-3229 / Nov 2020